索格列净治疗2型糖尿病患者心血管并发症的研究进展

Research progress of sotagliflozin in treatment of cardiovascular complications of patients with type 2 diabetes mellitus

2型糖尿病发病率逐年递增,随着病情发展可能出现心脏、肾脏、血管、神经等方面的并发症,其中心血管并发症是2型糖尿病患者死亡的重要原因。钠-葡萄糖共转运蛋白双重抑制剂索格列净可以减少2型糖尿病患者心血管并发症的发生,并改善心脏预后,提高患者生存率。

The incidence of type 2 diabetes mellitus(T2DM)is increasing,and its development can result in several complications,including cardiac,renal,vascular,and neurological problems.Cardiovascular complications are the leading cause of death in patients with T2DM.Sotagliflozin,a dual SGLT inhibitor,may reduce cardiovascular complications,and improve cardiac outcome and patients'survival rate.